Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 3/20 | 0.33 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280050 | 0.86 | CYP1A2 (0.57) | CYP1A2PPARGCA1CA9PRKCA | |
| SCHEMBL9754333 | 0.84 | CYP1A2 (0.60) | CYP1A2PPARGCA1CA9PRKCA | |
| SCHEMBL6856383 | 0.80 | CYP1A2 (0.55) | CYP1A2PPARGCA1CA9PRKCA | |
| SCHEMBL864461 | 0.79 | CYP1A2 (0.62) | CYP1A2PPARGCA1CA9PRKCA | |
| SCHEMBL9857060 | 0.79 | CYP1A2 (0.63) | CYP1A2PPARGKMT2ATARDBPPRKCA | |
| SCHEMBL3280318 | 0.79 | CYP1A2 (0.53) | CYP1A2PPARGCA1CA9PRKCA | |
| SCHEMBL4278956 | 0.78 | CYP1A2 (0.66) | CYP1A2PPARGCA1CA9PRKCA | |
| SCHEMBL864366 | 0.78 | CYP1A2 (0.66) | CYP1A2PPARGCA1CA9PRKCA | |
| SCHEMBL1114400 | 0.78 | CYP1A2 (0.51) | CYP1A2CA1CA9 | |
| SCHEMBL3278372 | 0.78 | CYP1A2 (0.51) | CYP1A2PPARGCA1CA9PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008119804-A1 | NEW METHODS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |